VivoSeq
Oncology

Pancreatic Adenocarcinoma

144

Pipeline Programs↗

48

Active Trials↗

67

Companies Involved↗

Pancreatic Adenocarcinoma is a highly competitive landscape with 144 programs across 67 companies. The most active players are Diakonos Oncology Corporation, Oncomatryx Biopharma S.L., Prism Pharma Co., Ltd.. 2 therapies are approved with 9 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

77/100

Pipeline Velocity

36/100

Mech. Concentration

7/100

Completion Rate

67/100

Attrition Rate

20/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

D

Diakonos Oncology Corporation

1 program

Phase 1O

Oncomatryx Biopharma S.L.

1 program

Phase 1P

Prism Pharma Co., Ltd.

1 program

Phase 1L

Legend Biotech USA Inc

1 program

Phase 1BeiGene logo

BeiGene

1 program

Phase 1S

Syndax Pharmaceuticals

1 program

Phase 1

Pipeline

Programs by Phase

Analysis

Modality Breakdown

84%

Small molecule

132 of 157 classified programs — the dominant modality here.

16%ALL OTHERSMonoclonal antibody1610%Protein / enzyme43%Peptide21%Cell therapy1<1%Gene therapy1<1%Vaccine1<1%

Small molecule leads; the ring shows all 157 classified programs, each share of the total. Modality classified for 100% of 165 pipeline programs.

Analysis

Trial Status

161

clinical trials

Completed67 · 42%
Recruiting25 · 16%
Terminated25 · 16%
Active, not recruiting19 · 12%
Unknown status13 · 8%
Withdrawn8 · 5%
Other4 · 2%

Clinical Trials

Trial Activity

161 trials

Th-1 Dendritic Cell Immunotherapy Plus Standard Chemotherapy for Pancreatic Adenocarcinoma
Recruiting·DDiakonos Oncology Corporation·Phase 1·NCT04157127·18 enrolled
Risk-adapted Adjuvant Chemotherapy Guided by the Tumour Stage for Operated Pancreatic Adenocarcinoma Following Neoadjuvant Chemotherapy With mFOLFIRINOX
Recruiting·UUniversity Hospital, Rouen·Phase 2/3·NCT07044453·390 enrolled
Perioperative NALIRIFOX (liposomal Irinotecan in Combination with Fluorouracil, Leucovorin, and Oxaliplatin) in Resectable Pancreatic Adenocarcinoma: Randomized Phase II Trial
Recruiting·TTaichung Veterans General Hospital·Phase 2·NCT06816914·84 enrolled
Pancreatic Adenocarcinoma Neoadjuvant Chemotherapy Before Surgery
Recruiting·HHamilton Health Sciences Corporation·Phase 2·NCT04452461·30 enrolled
TR-002 for the Treatment of Advanced, Unresectable or Metastatic Solid Tumors and Unresectable or Metastatic, Refractory Pancreatic Adenocarcinoma
Recruiting·UUniversity of California, Davis·Phase 1·NCT07189195·52 enrolled
A Study of NovoTTF-200T(P) in Combination With Gemcitabine and Nab-Paclitaxel for Resectable Pancreatic Adenocarcinoma
Recruiting·—·Phase 2·NCT05624918·38 enrolled
Clinical Trial of OMTX705 in Combination With Gemcitabine/Nab-Paclitaxel and Tislelizumab in Patients With Advanced/Metastatic Pancreatic Adenocarcinoma
Recruiting·OOncomatryx Biopharma S.L.·Phase 1·NCT07377045·69 enrolled
Neoadjuvant Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma
Recruiting·WWake Forest University Health Sciences·Phase 2·NCT05825066·64 enrolled
Chemo4METPANC Combination Chemokine Inhibitor, Immunotherapy, and Chemotherapy in Pancreatic Adenocarcinoma
Recruiting·—·Phase 2·NCT04543071·10 enrolled
Chemotherapy + Anakinra in Patients With Pancreatic Adenocarcinoma (PDAC)
Recruiting·—·Phase 2·NCT04926467·24 enrolled
BMS-986340 in Combination With Nivolumab, Gemcitabine and Nab-paclitaxel for the Treatment of Metastatic and Recurrent Pancreatic Adenocarcinoma
Recruiting·MMayo Clinic·Phase 2·NCT07226856·43 enrolled
Immunotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma
Recruiting·UUniversity of Louisville·Phase 2·NCT03080974·10 enrolled
Cemiplimab Plus Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma
Recruiting·UUniversity of California, San Diego·Phase 2·NCT06790602·43 enrolled
Evaluating NALIRIFOX vs Modified Gemcitabine, Nab-Paclitaxel and Cisplatin in Patients With Locally Advanced and Metastatic Pancreatic Adenocarcinoma
Recruiting·MMedical University of South Carolina·Phase 2·NCT07076212·52 enrolled
9-ING-41 Combined With Retifanlimab, Plus Modified FOLFIRINOX for Patients With Advanced Pancreatic Adenocarcinoma (RiLEY)
Recruiting·—·Phase 1·NCT06896188·12 enrolled
Page 1 of 11

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)